Interim Report Q1 – January – March, 2023 Redsense Medical AB (publ)
January – March 2023 · Net sales amounted to kSEK 6,824 (3,127), an increase by 118%. · Operating loss, EBIT amounted to kSEK 104 (2,076). · Result after tax amounted to kSEK 413 (-1,549). · Earnings per share was SEK 0.03 (-0.11) before and after dilution. Significant events during the period · On January 3, Redsense Medical announced that MSEK 4.75 of the previously disclosed record order had been delivered in December 2022, with the balance of the order planned for delivery in Q1. · On January 20, Redsense Medical announced that Jennie Kardell will join the